Relay Therapeutics reports Q4 net loss $0.32/share; cash $554.5M; zovegalisib milestones in 2026

Relay Therapeutics, Inc.

2025-FY EPS reported -$1.61 revenue$15,355,000

Q4 2025 net loss $54.9M ($0.32/share) vs $76.0M ($0.45) in Q4 2024; full year net loss $276.5M ($1.61/share).
Cash, cash equivalents and investments $554.5M at Dec 31 2025, down from $781.3M; runway into 2029.
Revenue $7.0M in Q4 2025 (Elevar license) vs $0 in Q4 2024; full year revenue $15.4M.
Zovegalisib Phase 1/2 breast cancer data at ESMO TAT March 16 in 57 patients at Phase 3 dose.
Initial vascular anomalies data expected 1H 2026; pediatric cohort in ReInspire trial opened early.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.